Non-Invasive Markers of Tumor Growth, Metastases, and Sensitivity to Anti-Neoplastic Therapy
Abstract
The goals of this application are to develop methods to non-invasively differentiate fast and slow growing (or aggressive vs. less aggressive) prostate tumors and also develop methods to evaluate response to anti-angiogenic agents. Validation of the results of the treatment studies will be based on tumor growth, metastases, and microvessel density measurement. To date, we have demonstrated that the R3327AT rat prostate tumor which is relatively radiation resistant has detectable lactate which is heterogeneously distributed once the tumor exceeds 600mm3. In contrast, the radiation sensitive, slow growing Dunning H does not have lactate that is detectable by NMR. DCE-MRI studies do not suggest differences in vascular parameters between slow and fast growing rat prostate tumors. The R3327AT tumor was shown to respond to anti-angiogenic therapy which could be predicted based on changes in lactate that were measured with 24 hours of starting treatment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2009
- Accession Number
- ADA524926
Entities
People
- Jason A Koutcher
Organizations
- Memorial Sloan Kettering Cancer Center